日本製薬企業のM&A成立前プロセスの分析

DOI Web Site 参考文献38件

書誌事項

タイトル別名
  • Analysis of Pre-M&A Process of Japanese Pharmaceutical Company:
  • ニホン セイヤク キギョウ ノ M A セイリツ マエ プロセス ノ ブンセキ アステラス セイヤク タンジョウ ノ ジレイ ケンキュウ
  • A Case Study of Astellas Pharma Merger
  • －アステラス製薬誕生の事例研究－

この論文をさがす

抄録

As the business environment for Japanese pharmaceutical companies intensified, Yamanouchi Pharmaceutical Co,. Ltd and Fujisawa Pharmaceutical Co,. Ltd completed the largest merger deal in the history of the Japanese pharmaceutical industry in April 2005, when Astellas Pharma was formed. In this report, we present a case study of the Astellas merger and use it as a basis for a discussion of M&A (Mergers and Acquisitions) process of Japanese pharmaceutical companies, especially focusing on the period up to and including the closing of merger. For this purpose, we conducted interviews with the frontline players including executive members of the company and analysis of publicly available information.<br>As a result, we found that both top managements and a merger Task Force played key roles in this case. Both Dr. Toichi Takenaka, CEO of Yamanouchi and Dr. Hatsuo Aoki, Fujisawa CEO have direct experience of the pressures and challenges facing their industry, and this drove the M&A process forward forcefully. Their growth oriented approach and fair and unselfish attitudes not only strengthen their relationship of mutual trust, but also were shared among the Task Force, which was vital in promoting a smooth pre-M&A process. The Task Force consisted of management and workforce layer and was given unprecedented authorization and leeway to participate proactively. Furthermore, it was also noteworthy that they had established OTC joint subsidiary before, which promoted the merger process of main business. These factors functioned as effective solutions to various problems of pre-M&A process in Astellas case.

収録刊行物

  • 医療と社会

    医療と社会 16 (3), 249-273, 2006

    公益財団法人 医療科学研究所

参考文献 (38)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ